Anaveon Welcomes Dr. Richard Sachse as Chief Medical Officer
Portfolio - People | Dec 18, 2024 | Syncona
Anaveon, a clinical-stage biotechnology firm focused on immuno-oncology, has appointed Dr. Richard Sachse as its new Chief Medical Officer, effective February 1, 2025. Dr. Sachse succeeds Dr. Eduard Gasal, who is departing for new opportunities. Sachse brings over 25 years of experience in the biopharma sector, having served in critical roles at SOTIO Biotech, Neovii, and Aeterna Zentaris, where he notably achieved FDA approval for Macimorelin. His extensive expertise spans the full pharmaceutical development spectrum, from preclinical stages to registration. As Chief Medical Officer, Sachse will oversee the advancement of Anaveon's lead program, ANV600, among other developmental initiatives. Anaveon is advancing selective cytokine receptor agonists for enhancing immune system responses in tumor treatment, with potential applications in a variety of oncological therapeutic combinations. CEO Andreas Katopodis acknowledges Sachse’s joining as pivotal, particularly as Anaveon continues to develop its pipeline, which is poised to bring novel therapeutics to the oncology sector.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- Switzerland – Anaveon is based in Basel, Switzerland, making this the primary geographical focus of the article.
Industry
- Biotechnology – The biotechnology sector involves companies engaged in the research and development of innovative medical treatments and technologies using biological processes. Anaveon operates in immuno-oncology, fitting within this sector.
- Pharmaceuticals – This industry focuses on the development, production, and marketing of medications. Anaveon's efforts in clinical trials and development of therapeutics like ANV600 align with the pharmaceutical sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Anaveon | Target Company | Company | A biotechnology company developing immuno-oncology therapeutics, located in Basel, Switzerland. |
| Syncona | Private Equity Firm | Company | A leading European healthcare investment company backing Anaveon. |
| Dr. Richard Sachse | Incoming Chief Medical Officer | Person | Newly appointed CMO at Anaveon with over 25 years of experience in the biopharmaceutical industry. |
| Dr. Eduard Gasal | Outgoing Chief Medical Officer | Person | Departing CMO of Anaveon, who contributed significantly to the company's clinical pipeline. |
| SOTIO Biotech | Previous Employer | Company | The former employer of Dr. Richard Sachse, where he served as Chief Medical Officer. |
| JW Communications | Media Relations | Company | Responsible for Anaveon's media communications. |
| Julia Wilson | Media Contact | Person | Media contact for Anaveon through JW Communications. |